ARS Investment Partners LLC Purchases 6,676 Shares of Regeneron Pharmaceuticals, Inc. $REGN

ARS Investment Partners LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 23.2% during the 4th quarter, HoldingsChannel.com reports. The fund owned 35,445 shares of the biopharmaceutical company’s stock after buying an additional 6,676 shares during the period. Regeneron Pharmaceuticals accounts for about 1.6% of ARS Investment Partners LLC’s investment portfolio, making the stock its 21st largest holding. ARS Investment Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $27,359,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently bought and sold shares of REGN. Meyer Handelman Co. increased its stake in Regeneron Pharmaceuticals by 0.6% during the 4th quarter. Meyer Handelman Co. now owns 2,878 shares of the biopharmaceutical company’s stock valued at $2,221,000 after purchasing an additional 18 shares in the last quarter. Gateway Investment Advisers LLC increased its stake in Regeneron Pharmaceuticals by 4.3% during the 4th quarter. Gateway Investment Advisers LLC now owns 464 shares of the biopharmaceutical company’s stock valued at $358,000 after purchasing an additional 19 shares in the last quarter. MGO One Seven LLC increased its stake in Regeneron Pharmaceuticals by 3.3% during the 4th quarter. MGO One Seven LLC now owns 589 shares of the biopharmaceutical company’s stock valued at $455,000 after purchasing an additional 19 shares in the last quarter. Whittier Trust Co. increased its stake in Regeneron Pharmaceuticals by 5.9% during the 4th quarter. Whittier Trust Co. now owns 357 shares of the biopharmaceutical company’s stock valued at $277,000 after purchasing an additional 20 shares in the last quarter. Finally, Boyd Watterson Asset Management LLC OH increased its stake in Regeneron Pharmaceuticals by 1.9% during the 4th quarter. Boyd Watterson Asset Management LLC OH now owns 1,072 shares of the biopharmaceutical company’s stock valued at $827,000 after purchasing an additional 20 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on REGN. Wells Fargo & Company decreased their price target on shares of Regeneron Pharmaceuticals from $825.00 to $800.00 and set an “equal weight” rating for the company in a research note on Thursday, April 30th. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, March 27th. Evercore upped their target price on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research note on Thursday, January 22nd. Zacks Research lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. Finally, TD Cowen upped their target price on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a research note on Thursday, April 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $826.59.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $698.25 on Friday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. The firm has a market cap of $73.82 billion, a price-to-earnings ratio of 17.01, a PEG ratio of 1.55 and a beta of 0.30. The company has a fifty day moving average price of $744.69 and a 200-day moving average price of $744.97.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The firm had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. During the same quarter in the prior year, the business posted $8.22 EPS. The business’s revenue was up 19.0% compared to the same quarter last year. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.1 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Wednesday, May 20th will be given a dividend of $0.94 per share. The ex-dividend date is Wednesday, May 20th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.16%.

Insider Activity

In related news, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at approximately $1,330,604.99. This represents a 49.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $705.24, for a total transaction of $70,524.00. Following the transaction, the director owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. The trade was a 0.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by corporate insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.